AAO 2026 – Clinical Trial Updates Part III

Emily H. Jung, MD
Duke Eye Center, Durham, NC

GLOW2 Study: Phase 3 Study of Tarcocimab for Diabetic Retinopathy
Margaret A. Chang, MD (Retinal Consultants Medical Group, Sacramento, CA)

Dr. Margaret Chang presented results from the Phase 3 GLOW2 superiority study evaluating intravitreal tarcocimab tedromer, which combines 4 mg of anti-VEGF antibody biopolymer conjugate (ABC) with 1 mg of unconjugated free antibody. Patients with moderately severe NPDR to mild PDR were randomized to receive 5 mg tarcocimab (n=130) or sham (n=125). The primary endpoint, the proportion of patients with an improvement of at least 2 steps in DRSS from baseline at week 48, was met (62.5% vs 3.3%; p<0.0001). A key secondary endpoint, the risk of developing a pre-specified sight-threatening complication, was also met (2.4% vs 15.8%, representing a 85% risk reduction compared to sham). Durability was assessed at 6 months after the last dose, with 59.3% of patients demonstrating a 2-step or greater improvement in DRSS. Patients were re-dosed with tarcocimab tedromer at that visit, and one month later, the proportion was similar (62.5%), with no significant change from the re-dosing visit. This suggests that the effect of tarcocimab tedromer lasts at least 6 months in this population. Tarcocimab tedromer was well tolerated, with no reports of intraocular inflammation, vasculitis, or vascular occlusion. In the discussion, Dr. Carl Awh asked why physicians would favor tarcocimab tedromer over existing anti-VEGF agents for diabetic retinopathy. Dr. Chang responded that the drug performed better than expected and that the ABC platform increases free antibody durability, which could allow for dosing every 6 months or less frequently.

Efficacy and Safety of Subretinal Sura-vec Gene Therapy in Subjects with CI-DME: First-Time Results from the Phase 2 ELAAVATE Trial
Arshad M. Khanani, MD (Sierra Eye Associates, Reno, NV)

Dr. Arshad Khanani discussed Phase 2 ELAAVATE trial results for subretinal surabgene lomparvovec (sura-vec, formerly ABBV-RGX-314) for center-involving DME. Sura-vec is an AAV8 vector encoding an anti-VEGF antibody fragment. Preliminary data were reported for 11 patients with active center-involving DME previously treated with anti-VEGF. Patients received low-dose sura-vec (6.4 x1010 GC/eye, n=4), high-dose sura-vec (1.3 x 1011 GC/eye, n=5), or 2 mg aflibercept every 8 weeks as a control (n=2). In the sura-vec groups, mean BCVA improved by 6 letters with low dose and 15 letters with high dose, and mean CST decreased by 60 and 183 µm, respectively. A 70-80% reduction in anti-VEGF injection burden was also observed in both sura-vec groups. No chorioretinitis, vasculitis, occlusion, or hypotony were reported; worsening cataract and peripheral retinal pigmentary changes were observed. In the discussion, Dr. Khanani described this as a proof-of-concept study. He said he favors a surgical approach for the right patient, particularly those who cannot maintain the injection burden and are at risk of being lost to follow-up.

BRUNELLO: 1-Year Pivotal Trial Results of Remigromig (MK-3000, formerly EYE103) for the Treatment of Diabetic Macular Edema
Donald J. D’Amico, MD (Weill Cornell Medical College, New York, NY)

Dr. Donald D’Amico presented 1-year results from the pivotal Phase 2b/3 BRUNELLO trial of intravitreal remigromig (MK-3000) for DME. Remigromig is a tri-specific antibody that activates the Wnt pathway to re-establish the blood-retinal barrier, a mechanism distinct from VEGF inhibition. Patients were randomized to 0.5 mg remigromig (n=327), 0.8 mg remigromig (n=330), or 0.5 mg ranibizumab (n=327), every 4 weeks. Ranibizumab was selected as the comparator because it is the only agent approved for monthly dosing in DME. The primary endpoint, mean change in BCVA, demonstrated that remigromig was non-inferior to ranibizumab. Change in CST, a secondary endpoint, was comparable. Adverse events were generally balanced between arms with the exception of PDR events, which were more frequent with remigromig (6.7% vs 6.1% vs 0.9% for 0.5 mg remigromig vs 0.8 mg remigromig vs ranibizumab). Dr. D’Amico suggested this may reflect natural disease progression, noting that remigromig is designed to restore barrier integrity rather than target new vessel growth, whereas ranibizumab directly inhibits VEGF-mediated neovascularization.

52-Week Efficacy and Safety Data From the Global Phase 3 OCS-01 DIAMOND Program in Diabetic Macular Edema
Baruch D. Kuppermann, MD, PhD (Gavin Herbert Eye Institute, University of California, Irvine, CA)

Dr. Baruch Kuppermann presented 52-week data from the Phase 3 DIAMOND program of OCS-01, a topical high-concentration dexamethasone eye drop (15 mg/mL) for DME. Patients with DME were randomized to OCS-01 (n=200 in DIAMOND-1, n=200 in DIAMOND-2) or vehicle (n=203 and n=201, respectively). The primary endpoint, least squares mean change in BCVA at week 52, was not met (OCS-01 vs vehicle: +1.2 vs +5.1 letters in DIAMOND-1; +4.6 vs +5.2 letters in DIAMOND-2). Functional and anatomic outcomes were discordant, as OCS-01 produced a significantly greater reduction in CST than vehicle through week 48 in DIAMOND-1 and through week 52 in DIAMOND-2. OCS-01 was well tolerated, though, as expected, elevated IOP and cataracts were more frequent in the treatment group. In the discussion, Dr. Rishi Singh asked whether underdosing or missed doses could have contributed to the disconnect between visual and anatomic results. Dr. Kuppermann acknowledged that patients frequently did not take the drops as instructed and noted that the visual acuity data were quite variable.